Sophiris Bio Applies for Voluntary Delisting from TSX

07-11-2013 Business Wire HealthComments (0)

Biotechnology

Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS), a biopharmaceutical company developing a clinical-stage, targeted treatment for BPH, announced voluntary delisting from Toronto Stock Exchange.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top